Ziopharm's Ad-RTS-hIL-12 plus Veledimex Fast Track'd for rGBM; shares up 8% premarket

|About: ZIOPHARM Oncology, Inc. (ZIOP)|By:, SA News Editor

The FDA has granted Fast Track Designation for Ziopharm Oncology's (NASDAQ:ZIOP) Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex, for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults.

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

Shares are up 8% premarket.

Subscribe for full text news in your inbox